(2R)-2-{[1-({[(3S)-1-(carboxymethyl)-2-oxo-2,3,4,5-tetrahydro-1H-1-benzazepin-3-yl]amino}carbonyl)cyclopentyl]methyl}-4-phenylbutanoic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2R)-2-{[1-({[(3S)-1-(carboxymethyl)-2-oxo-2,3,4,5-tetrahydro-1H-1-benzazepin-3-yl]amino}carbonyl)cyclopentyl]methyl}-4-phenylbutanoic acid
• 英文别名: (2R)-2-[[1-[[(3S)-1-(carboxymethyl)-2-oxo-4,5-dihydro-3H-1-benzazepin-3-yl]carbamoyl]cyclopentyl]methyl]-4-phenylbutanoic acid
• 化学式: C₂₉H₃₄N₂O₆
• 分子量: 506.599
• InChiKey: RSRHEOWMSRYTNB-PKTZIBPZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  37
• 可旋转键数：
  10
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  124
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  tert-butyl (3S,2'R)-3-{1-[2'-(tert-butoxycarbonyl)-4'-phenylbutyl]cyclopentane-1-carbonylamino}-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepine-1-acetate 生成 (2R)-2-{[1-({[(3S)-1-(carboxymethyl)-2-oxo-2,3,4,5-tetrahydro-1H-1-benzazepin-3-yl]amino}carbonyl)cyclopentyl]methyl}-4-phenylbutanoic acid
  参考文献：
  名称：

  Benzazepine-, benzoxazepine- and benzothiazepine-n-acetic acid

  摘要：

  具有中性内肽酶（NEP）抑制活性的化合物对应于式I 其中R.sup.1是一个较低的烷氧基-较低烷基基团，其较低的烷氧基团被较低的烷氧基取代，或者是一个苯基-较低烷基或苯氧基-较低烷基基团，该基团可以选择性地在苯环上被较低烷基、较低烷氧基或卤素取代，或者是一个萘基-较低烷基基团，其中A是CH.sub.2、O或S，R.sup.2是氢或卤素，R.sup.3是氢或卤素，R.sup.4是氢或形成生物易降解酯的基团，R.sup.5是氢或形成生物易降解酯的基团，以及其生理上可接受的酸盐。

  公开号：

  US05677297A1

文献信息

• Pharmaceutical compositions and method for the treatment of hypertension
  申请人：——

  公开号：US20020052361A1

  公开（公告）日：2002-05-02

  The present invention relates to the use of benzazepine-N-acetic acid derivatives which contain an oxo-group in the &agr;-position to the nitrogen atom and are substituted in position 3 by a 1-(carboxyalkyl)cyclo-entylcarbonylamino radical, and their salts and biolabile esters for the treatment of hypertension, particularly for the treatment of certain forms of secondary hypertension, in larger mammals and particularly humans, and for the production of pharmaceutical compositions suitable for this treatment. The cause of the hypertension to be treated may have a wide variety of origins. The invention particularly relates to the treatment of those forms of secondary hypertension which may occur as a result of various non-cardiac diseases.

  本发明涉及苯扎西平-N-乙酸衍生物的用途，该衍生物在氮原子的&agr;-位上含有一个氧代基团，并在第3位上被1-(羧基烷基)环戊基羰基氨基取代，它们的盐和生物可降解酯可用于治疗大型哺乳动物，特别是人类的高血压，尤其是治疗某些形式的继发性高血压，还可用于生产适用于这种治疗的药物组合物。需要治疗的高血压的病因可能多种多样。本发明尤其涉及治疗那些可能因各种非心脏病而引起的继发性高血压。
• Compounds with NEP/MP-inhibitory activity and uses thereof
  申请人：Solvay Pharmaceuticals GmbH

  公开号：US20040162345A1

  公开（公告）日：2004-08-19

  Compounds having combined, particularly concurrent, inhibitory activity on neutral endopeptidase (NEP) and on a novel metalloprotease designated IGS5, or of a pharmaceutically acceptable salt or solvate or biolabile ester thereof, and related methods for treating and for the manufacture of a pharmaceutical composition for a mammal, preferably a larger mammal such as a human, suffering from or being susceptible to a disease or condition which can be alleviated or inhibited by combined or concurrent inhibition of NEP and IGS5. Treatments for diseases or conditions where big-ET-1 levels are elevated, or where ET-1 is upregulated, where such diseases or conditions can be alleviated or inhibited by combined or concurrent inhibition of NEP and IGS5.

  对中性内肽酶(NEP)和一种被命名为IGS5的新型金属蛋白酶或其药学上可接受的盐或溶解物或生物可降解酯具有联合、特别是并发抑制活性的化合物，以及用于治疗和制造药物组合物的相关方法，该药物组合物用于哺乳动物，最好是较大的哺乳动物，如人类，患有或易患可通过联合或并发抑制NEP和IGS5而减轻或抑制的疾病或病症。治疗big-ET-1水平升高或ET-1上调的疾病或病症，这些疾病或病症可通过联合或同时抑制NEP和IGS5而减轻或抑制。
• Method and pharmaceutical compositions for treating or inhibiting renal dysfunctions, diseases or disorders, particularly in diabetic patients
  申请人：Thormaehlen Dirk

  公开号：US20050137183A1

  公开（公告）日：2005-06-23

  Treatment and/or inhibition of renal dysfunction, disease or disorder in larger mammals, and particularly in humans, especially in human patients suffering from diabetes, using benzazepine-N-acetic acid derivatives which contain an oxo-group in the α-position to the nitrogen atom and are substituted in position 3 by a 1-(carboxyalkyl)cyclopentylcarbonylamino radical, and/or salts or biolabile esters or physiologically acceptable solvates thereof, and production of pharmaceutical compositions and products suitable for treatment and/or inhibition of renal dysfunction, disease or disorder, particularly in diabetic patients, but also in patients with syndrome X or in patients with a renal dysfunction, disease and/or disorder, which patients are additionally hypertensive, obese, hyperglycemic and/or subject to a metabolic disorder.

  使用苯并氮杂卓-N-乙酸衍生物治疗和/或抑制大型哺乳动物，特别是人类，尤其是患有糖尿病的人类患者的肾功能障碍、疾病或紊乱，该衍生物在氮原子的α位含有一个氧代基团，并在第3位被1-(羧基烷基)环戊基羰基氨基取代，和/或其盐或生物可降解酯或生理上可接受的溶液、生产适用于治疗和/或抑制肾功能障碍、疾病或紊乱的药物组合物和产品，特别是糖尿病患者，但也适用于 X 综合征患者或肾功能障碍、疾病和/或紊乱患者，这些患者还伴有高血压、肥胖、高血糖和/或代谢紊乱。
• Neutral endopeptidase (NEP) and human soluble endopeptidase (hSEP) inhibitors for prophylaxis and treatment of neuro-degenerative disorders
  申请人：Ikonomidou Hrissanthi

  公开号：US20050153936A1

  公开（公告）日：2005-07-14

  The invention relates to a novel use of known benzazepine, benzoxazepine, benzo-thiazepine-N-acetic acid and phosphono-substituted benzazepinone derivatives having neutral endopeptidase (NEP) and/or human soluble endopeptidase (hSEP) inhibitory activity. The compounds of the invention are useful for the preparation of pharmaceutical compositions for prophylaxis and treatment of neurodegenerative disorders. The compounds of the invention are known from the European patents EP 0 733 642 and EP 0 916 679, and can be described by the general formulae (1): wherein the symbols have the meanings as given above in the description.

  本发明涉及具有中性内肽酶（NEP）和/或人类可溶性内肽酶（hSEP）抑制活性的已知苯并氮平、苯并氧氮平、苯并-硫氮平-N-乙酸和膦酸取代的苯并氮酮衍生物的新用途。 本发明的化合物可用于制备预防和治疗神经退行性疾病的药物组合物。 本发明的化合物已知于欧洲专利 EP 0 733 642 和 EP 0 916 679，可用通式（1）描述：其中符号的含义如上文所述。
• PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF RENAL DYSFUNCTION
  申请人：Solvay Pharmaceuticals GmbH

  公开号：EP1687006B1

  公开（公告）日：2007-11-14